Beat The Denominator

MicroStrategy (MSTR) is presented as a "coiled spring," offering a compelling investment as its stock price has become cheaper relative to its underlying Bitcoin holdings. A potential catalyst to watch for is the announcement of a new preferred share ATM offering, which could trigger a significant price increase. Consider MSTR for long-term exposure to Bitcoin, as it is behaving more like a stable, blue-chip treasury company. For investors with a higher risk tolerance, Metaplanet and Semler Scientific (SMLR) provide more volatile plays on the same Bitcoin treasury strategy. Due to decreasing volatility in MSTR, it is advisable to hold the stock directly and avoid trading options on it.

The recent drop in Hims & Hers Health (HIMS) stock is considered a significant buying opportunity due to a market overreaction. Wall Street has misjudged the termination of the Novo Nordisk (NVO) partnership, as the affected GLP-1 business only accounts for 15-20% of total revenue. The core investment thesis is that HIMS is a disruptive telehealth platform with a strong, customer-centric model for personalized care. A potential future catalyst for the stock could be a new weight-loss drug partnership with Eli Lilly (LLY). Investors should focus on the company's long-term potential to disrupt the primary care market, not just the short-term weight loss narrative.